Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome

Gynecologic Oncology

Volumn 142, Issue 3, 2016, Pages 458-464

  Gao, Bo ^a,b   Lindemann, Kristina ^a,b,c   Anderson, Lyndal ^d   Fereday, Sian ^e   Hung, Jillian ^a,b   Alsop, Kathryn ^e   Tothill, Richard W ^e   Gebski, Val ^b   Kennedy, Catherine ^a,b   Balleine, Rosemary L ^b,f   Harnett, Paul R ^a,b   Bowtell, David D L ^e,g,h,i   DeFazio, Anna ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f Center for Infectious Diseases and Microbiology (CIDM) Institute of Clinical Pathology and Medical Research (ICPMR)   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Interval debulking; Molecular subtypes; Neoadjuvant chemotherapy; Ovarian cancer; Primary peritoneal cancer; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DEATH; FEMALE; GENE EXPRESSION PROFILING; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; SEROUS OVARIAN CANCER; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; CASE CONTROL STUDY; CLINICAL TRIAL; CYSTADENOCARCINOMA, SEROUS; MIDDLE AGED; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; PERITONEAL NEOPLASMS;

AGED; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84990204732     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.06.023     Document Type: Article

References (40)

1. [1] Swerdlow, M., Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. Am. J. Obstet. Gynecol. 77 (1959), 197–200.
2. [2] Eltabbakh, G.H., Piver, M.S., Natarajan, N., Mettlin, C.J., Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet. Gynecol. 91 (1998), 254–259.
3. [3] Rebbeck, T.R., Lynch, H.T., Neuhausen, S.L., Narod, S.A., Van't Veer, L., Garber, J.E., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346 (2002), 1616–1622.
4. [4] Tobacman, J.K., Greene, M.H., Tucker, M.A., Costa, J., Kase, R., Fraumeni, J.F. Jr., Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 2 (1982), 795–797.
5. [5] Kindelberger, D.W., Lee, Y., Miron, A., Hirsch, M.S., Feltmate, C., Medeiros, F., et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 31 (2007), 161–169.
6. [6] Lee, Y., Miron, A., Drapkin, R., Nucci, M.R., Medeiros, F., Saleemuddin, A., et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211 (2007), 26–35.
7. [7] Perets, R., Wyant, G.A., Muto, K.W., Bijron, J.G., Poole, B.B., Chin, K.T., et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24 (2013), 751–765.
8. [8] Leeper, K., Garcia, R., Swisher, E., Goff, B., Greer, B., Paley, P., Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol. Oncol. 87 (2002), 52–56.
9. [9] Medeiros, F., Muto, M.G., Lee, Y., Elvin, J.A., Callahan, M.J., Feltmate, C., et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30 (2006), 230–236.
10. [10] Przybycin, C.G., Kurman, R.J., Ronnett, B.M., Shih Ie, M., Vang, R., Are all pelvic (nonuterine) serous carcinomas of tubal origin?. Am. J. Surg. Pathol. 34 (2010), 1407–1416.
11. [11] Chene, G., Tchirkov, A., Pierre-Eymard, E., Dauplat, J., Raoelfils, I., Cayre, A., et al. Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions. Clin. Cancer Res. 19 (2013), 2873–2882.
12. [12] Folkins, A.K., Jarboe, E.A., Saleemuddin, A., Lee, Y., Callahan, M.J., Drapkin, R., et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol. Oncol. 109 (2008), 168–173.
13. [13] Jordan, S.J., Green, A.C., Whiteman, D.C., Moore, S.P., Bain, C.J., Gertig, D.M., et al. Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int. J. Cancer 122 (2008), 1598–1603.
14. [14] Schnack, T.H., Sorensen, R.D., Nedergaard, L., Hogdall, C., Demographic clinical and prognostic characteristics of primary ovarian, peritoneal and tubal adenocarcinomas of serous histology–a prospective comparative study. Gynecol. Oncol. 135 (2014), 278–284.
15. [15] Grant, D.J., Moorman, P.G., Akushevich, L., Palmieri, R.T., Bentley, R.C., Schildkraut, J.M., Primary peritoneal and ovarian cancers: an epidemiological comparative analysis. Cancer Causes Control 21 (2010), 991–998.
16. [16] Tothill, R.W., Tinker, A.V., George, J., Brown, R., Fox, S.B., Lade, S., et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14 (2008), 5198–5208.
17. [17] The Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
18. [18] Tan, T.Z., Miow, Q.H., Huang, R.Y., Wong, M.K., Ye, J., Lau, J.A., et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med. 5 (2013), 983–998.
19. [19] Helland, A., Anglesio, M.S., George, J., Cowin, P.A., Johnstone, C.N., House CM, et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One, 6, 2011, e18064.
20. [20] Mulhollan, T.J., Silva, E.G., Tornos, C., Guerrieri, C., Fromm, G.L., Gershenson, D., Ovarian involvement by serous surface papillary carcinoma. Int. J. Gynecol. Pathol. 13 (1994), 120–126.
21. [21] Dalrymple, J.C., Bannatyne, P., Russell, P., Solomon, H.J., Tattersall, M.H., Atkinson, K., et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 64 (1989), 110–115.
22. [22] Fromm, G.L., Gershenson, D.M., Silva, E.G., Papillary serous carcinoma of the peritoneum. Obstet. Gynecol. 75 (1990), 89–95.
23. [23] Bloss, J.D., Liao, S.Y., Buller, R.E., Manetta, A., Berman, M.L., McMeekin, S., et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol. Oncol. 50 (1993), 347–351.
24. [24] Killackey, M.A., Davis, A.R., Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol. Oncol. 51 (1993), 171–174.
25. [25] Gooneratne, S., Sassone, M., Blaustein, A., Talerman, A., Serous surface papillary carcinoma of the ovary: a clinicopathologic study of 16 cases. Int. J. Gynecol. Pathol. 1 (1982), 258–269.
26. [26] Mills, S.E., Andersen, W.A., Fechner, R.E., Austin, M.B., Serous surface papillary carcinoma. A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma. Am. J. Surg. Pathol. 12 (1988), 827–834.
27. [27] Halperin, R., Zehavi, S., Langer, R., Hadas, E., Bukovsky, I., Schneider, D., Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer. Int. J. Gynecol. Cancer 11 (2001), 403–408.
28. [28] Rothacker, D., Mobius, G., Varieties of serous surface papillary carcinoma of the peritoneum in northern Germany: a thirty-year autopsy study. Int. J. Gynecol. Pathol. 14 (1995), 310–318.
29. [29] Shimizu, Y., Kamoi, S., Amada, S., Akiyama, F., Silverberg, S.G., Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82 (1998), 893–901.
30. [30] Rustin, G.J., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int. J. Gynecol. Cancer 21 (2011), 419–423.
31. [31] Johnatty, S.E., Beesley, J., Paul, J., Fereday, S., Spurdle, A.B., Webb, P.M., et al. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin. Cancer Res. 14 (2008), 5594–5601.
32. [32] Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J. Clin. Oncol. 30 (2012), 2654–2663.
33. [33] Howitt, B.E., Hanamornroongruang, S., Lin, D.I., Conner, J.E., Schulte, S., Horowitz, N., et al. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am. J. Surg. Pathol. 39 (2015), 287–293.
34. [34] Griffiths, C.T., Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer Inst. Monogr. 42 (1975), 101–104.
35. [35] Liu, Z., Beach, J.A., Agadjanian, H., Jia, D., Aspuria, P.J., Karlan, B.Y., et al. Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecol. Oncol. 139 (2015), 394–400.
36. [36] Vergote, I., Trope, C.G., Amant, F., Kristensen, G.B., Ehlen, T., Johnson, N., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363 (2010), 943–953.
37. [37] Kehoe, S., Hook, J., Nankivell, M., Jayson, G.C., Kitchener, H., Lopes, T., et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386 (2015), 249–257.
38. [38] Rauh-Hain, J.A., Nitschmann, C.C., Worley, M.J. Jr., Bradford, L.S., Berkowitz, R.S., Schorge, J.O., et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol. Oncol. 129 (2013), 63–68.
39. [39] Ryner, L., Guan, Y., Firestein, R., Xiao, Y., Choi, Y., Rabe, C., et al. Upregulation of periostin and reactive stroma is associated with primary chemoresistance and predicts clinical outcomes in epithelial ovarian cancer. Clin. Cancer Res. 21 (2015), 2941–2951.
40. [40] Olive, K.P., Jacobetz, M.A., Davidson, C.J., Gopinathan, A., McIntyre, D., Honess, D., et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 (2009), 1457–1461.